NCT06092957招募中3 期
Reduced-dose Radiotherapy With/Without Concurrent Chemotherapy Versus Standard Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma Who Achieved Complete Response After Induction Chemotherapy Plus Immunotherapy: a Randomized, Open-label, Multicenter, Phase III Trial
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 504 人开始时间: 2023年10月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 504
- 试验地点
- 1
- 主要终点
- Progress-Free Survival (PFS)
研究概览
简要总结
This prospective trial aims to enroll patients with high-risk stage III-IVA (AJCC 8th, except T3N0) locoregionally-advanced nasopharyngeal carcinoma (LANPC). Under the condition of full course of PD-1/PD-L1 blockades, patients who achieved both radiological and biological complete response after 3 cycles of platinum-based chemotherapy plus PD-1/PD-L1 blockades will be randomized in a 1:1:1 ratio to receive reduced-dose radiotherapy (60Gy/30F) alone or reduced-dose radiotherapy plus concurrent chemotherapy or standard dose radiotherapy (70Gy/33F) with concurrent chemotherapy. To solve the urgent problem of whether patients with high-risk advanced nasopharyngeal carcinoma are suitable for downgrade treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or type III).
- •Tumor staged as III-IVA (AJCC 8th, except T3N0).
- •Patients who achieved both radiological and biological CR according to the RECIST criteria on the basis of MRI, PET-CT and endoscopic biopsy, and EBV DNA load =0 copies/mL (or lower than the test line) after 3 cycles of induction therapy of platinum-based chemotherapy plus immunotherapy.
- •Eastern Cooperative Oncology Group performance status ≤
- •Adequate organ function:
- •Adequate marrow function: neutrocyte count≥4×10e9/L, hemoglobin ≥90g/L and platelet count ≥100×10e9/L.
- •Adequate liver and kidney function: Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) ≤2.5×upper limit of normal (ULN), and bilirubin ≤ 2.5×ULN.; creatinine clearance rate ≥ 60 ml/min or creatinine of no more than 1.5 times the upper normal limit.
- •Patients must be informed of the investigational nature of this study and give written informed consent.
排除标准
- •Patients who are evaluated as PR or SD or PD or EBV DNA load of >0 copies/mL after 3 cycles of induction therapy of platinum-based chemotherapy plus PD-1/PD-L1 blockades.
- •The laboratory examination value does not meet the relevant standards within 7 days before enrollment.
- •Patients have received prior chemotherapy, immunotherapy, targeted therapy, or surgery (other than diagnostic treatment).
- •Subjects who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs.
- •Active central nervous system (CNS) metastases (indicated by clinical symptoms, cerebral edema, steroid requirement, or progressive disease).
- •Grade ≥2 epistaxis (defined as the need for medical intervention such as nasal tamponade, cautery, topical vasoconstrictors, according to CTCAE 5.0) within 1 month prior to enrollment; Macroscopic hemoptysis or hematemesis) is defined as ≥1/2 teaspoon of bright red blood, or a blood clot with little/no sputum on each cough). (Patients with mixed sputum-blood occasionally may be enrolled).
- •Patients with hypertension who cannot be reduced to the normal range by antihypertensive drug treatment (systolic blood pressure > 140 mmHg/diastolic blood pressure > 90 mmHg), patients with ≥ grade II coronary heart disease, arrhythmia (including QTc interval prolongation > 450 ms in men and > 470 ms in women) and cardiac insufficiency.
- •Patients currently take warfarin, heparin, aspirin (> 325 mg/day) or other NSAIDs known to inhibit platelet function, ticlopidine, clopidogrel, or cilostazol. (Patients can be enrolled if they discontinue these drugs 10 days prior to the commence of study and meet the requirements of coagulation in the enrollment criteria).
- •Patients with other malignancies (except for cervical cancer, basal cell carcinoma or squamous cell carcinoma of the skin, localized prostate cancer, and ductal carcinoma in situ who have undergone curative treatment).
- •Has a known history of interstitial lung disease.
- •Known history of hypersensitivity to any components of the PD-1/PD-L1 blockades formulation or other monoclonal antibodies.
- •Has a known history of allergic reactions to the drugs in the study (gemcitabine, cisplatin, docetaxel, abraxane, paclitaxel ).
- •Has active autoimmune disease or any condition that requires systemic corticosteroid or immunosuppressive therapy, including but not limited to the following: rheumatoid arthritis, pneumonitis, colitis (inflammatory bowel disease), hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. Subjects with the following conditions will not be excluded from this study: asthma that requires intermittent use of bronchodilators, hypothyroidism stable on hormone replacement, vitiligo, Graves' disease, or Hashimoto's disease. Additional exceptions may be made with medical monitor approval.
- •Complications requiring long-term use of immunosuppressive drugs or systemic or local use of immunosuppressive-dose corticosteroids.
- •HIV positive; HBsAg positive and HBV DNA copy number positive (quantitative detection ≥ 1000 cps/ml); chronic hepatitis C with blood screening positive (HCV antibody positive).
- •Has a known history of active TB (bacillus tuberculosis) within 1 year; anti-TB treatment is ongoing or within 1 year prior to screening.
- •Has received a live vaccine; or a systematic glucocorticoid therapy ; or any anti-infective vaccine (e.g. influenza vaccine, varicella vaccine, etc.) ; any Chinese anti-tumor herbs within 4 weeks prior to enrollment.
- •Pregnancy or breastfeeding.
- •Other patients who were considered unsuitable by the treating physicians.
研究组 & 干预措施
Induction chemotherapy plus conventional concurrent chemoradiotherapy
Active Comparator
干预措施: Cisplatin-based induction chemotherapy (Drug)
Induction chemotherapy plus conventional concurrent chemoradiotherapy
Active Comparator
干预措施: Full course of PD-1/PD-L1 blockades (Drug)
Induction chemotherapy plus conventional concurrent chemoradiotherapy
Active Comparator
干预措施: Standard-dose IMRT (Radiation)
Induction chemotherapy plus conventional concurrent chemoradiotherapy
Active Comparator
干预措施: Concurrent Chemotherapy (Drug)
Induction chemotherapy plus reduced-dose radiotherapy and concurrent chemotherapy
Experimental
干预措施: Cisplatin-based induction chemotherapy (Drug)
Induction chemotherapy plus reduced-dose radiotherapy and concurrent chemotherapy
Experimental
干预措施: Full course of PD-1/PD-L1 blockades (Drug)
Induction chemotherapy plus reduced-dose radiotherapy and concurrent chemotherapy
Experimental
干预措施: Reduced-dose IMRT (Radiation)
Induction chemotherapy plus reduced-dose radiotherapy and concurrent chemotherapy
Experimental
干预措施: Concurrent Chemotherapy (Drug)
Induction chemotherapy plus reduced-dose radiotherapy alone
Experimental
干预措施: Cisplatin-based induction chemotherapy (Drug)
Induction chemotherapy plus reduced-dose radiotherapy alone
Experimental
干预措施: Full course of PD-1/PD-L1 blockades (Drug)
Induction chemotherapy plus reduced-dose radiotherapy alone
Experimental
干预措施: Reduced-dose IMRT (Radiation)
结局指标
主要结局
Progress-Free Survival (PFS)
时间窗: 3 years
Defined as time from randomization to locoregional or distant metastasis relapse or death from any cause, whichever occurred first.
次要结局
- Overall Survival (OS)(3 years)
- Distant Metastasis-Free Survival (DMFS)(3 years)
- The proportion of patients with treatment related late complications(3 years)
- Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&N35)(3 years)
- Locoregional Relapse-Free Survival (LRRFS)(3 years)
- The proportion of patients with treatment related acute complications(1 year)
- Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0)(3 years)
研究者
Ming-Yuan Chen
Principal Investigator
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of RecurrenceCutaneous Squamous Cell Carcinoma (CSCC)NCT06692556Centre Leon Berard266
已完成
3 期
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' TumorStage III Kidney Wilms TumorStage IV Kidney Wilms TumorNCT00379340Children's Oncology Group395
招募中
3 期
Adjuvant Radiotherapy in High Risk Locally Advanced DTCThyroid CancerNCT06558981Fudan University124
Unknown
3 期
HFSRT With Concurrent TMZ for Large BMsBrain MetastasesChemotherapyRadiotherapyNCT03778541Chinese Academy of Medical Sciences224
招募中
3 期
Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT02610010Sun Yat-sen University462